Benzinga's Top #PreMarket Losers

slipped 19.29 percent to $16.95 in pre-market trading after the company reported a loss in the first quarter. The Brooklyn, New York-based company posted a quarterly net loss of $36.6 million, or $0.84 per share, versus a year-ago loss of $0.5 million, or $0.01 per share.

fell 8.61 percent to $9.76 in pre-market trading following the announcement of Hep C collaboration with Janssen Pharmaceuticals, a

unit. UBS downgraded Achillion Pharmaceuticals from Buy to Neutral.

shares dropped 6.58 percent to $67.10 in pre-market after the company reported downbeat results for its first quarter.

shares fell 4.37 percent to $22.29 in pre-market trading after falling 3.96 percent on Tuesday.

shares declined 3.75 percent to $55.15 in pre-market trading after the company announced a secondary offering of 20 million commons shares by selling shareholders.